- For the University
- For external organisations
- Contact us
The PREDICT breast treatment tool, designed to help doctors determine the ideal course of treatment following a patients’ breast cancer surgery, is now available to oncology healthcare professionals globally via ONCOassist, an interactive, clinical decision support app. ONCOassist provides tools that oncology professionals rely on daily.
A mathematical model designed for patients and doctors to help them decide on the ideal course of treatment following breast cancer surgery, PREDICT was developed by a partnership among The Breast Unit at Cambridge University Hospitals NHS Trust (CUH), the University of Cambridge Department of Oncology and the NHS Eastern Cancer Registry and Information Centre (ECRIC). The technology was licensed to ONCOassist by Cambridge Enterprise, the commercialisation arm of the University of Cambridge.
The addition of the PREDICT breast algorithm will enhance our platform with new functionality to help clinicians make informed decisions about adjuvant treatment following breast cancer surgery.Dr Richard Bambury
PREDICT is the first breast cancer model of this type to include tumour HER2 and KI67 status in its decision making algorithm.
Making the PREDICT tool available through ONCOassist expands the tool’s reach to a global audience. It is available both on desktop and mobile devices (iOS and Android) in an easy-to-use and interactive format.
ONCOassist also includes adjuvant decision support calculators for other cancers, useful formulas, prognostic algorithms, American Joint Cancer Committee (AJCC) staging and Common Toxicity Criteria for Adverse Events (CTCAE) tools.
ONCOassist is used widely around the world, and is offered as a member benefit by the European Society of Medical Oncology. It is one of the few medical apps on the market to have Cambridge Enterprise approval, meaning it is fully compliant with EU medical device standards.
ONCOassist Chief Medical Officer Dr Richard Bambury said: “The addition of the PREDICT breast algorithm will enhance our platform with new functionality to help clinicians make informed decisions about adjuvant treatment following breast cancer surgery. This will be of huge benefit to our global userbase.” Professor Paul Pharoah, of the University of Cambridge, who was part of the development team, said: “PREDICT is used by cancer doctors from around the world. We hope that including the model in OncoAssist will encourage more doctors to use the model and help improve outcomes for breast cancer patients.”